These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 34898381)

  • 1. Heterologous prime-boost vaccination against COVID-19: is it safe and reliable?
    Choudhary OP; Priyanka ; Ahmed JQ; Mohammed TA; Singh I; Rodriguez-Morales AJ
    Hum Vaccin Immunother; 2021 Dec; 17(12):5135-5138. PubMed ID: 34898381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reactogenicity and immunogenicity of heterologous prime-boost immunization with COVID-19 vaccine.
    Nguyen TT; Quach THT; Tran TM; Phuoc HN; Nguyen HT; Vo TK; Vo GV
    Biomed Pharmacother; 2022 Mar; 147():112650. PubMed ID: 35066301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity and safety of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine: a systematic review.
    Lv J; Wu H; Xu J; Liu J
    Infect Dis Poverty; 2022 May; 11(1):53. PubMed ID: 35562753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study.
    Wanlapakorn N; Suntronwong N; Phowatthanasathian H; Yorsaeng R; Vichaiwattana P; Thongmee T; Auphimai C; Srimuan D; Thatsanatorn T; Assawakosri S; Kanokudom S; Poovorawan Y
    Hum Vaccin Immunother; 2022 Dec; 18(1):2029111. PubMed ID: 35209809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines.
    Cohen G; Jungsomsri P; Sangwongwanich J; Tawinprai K; Siripongboonsitti T; Porntharukchareon T; Wittayasak K; Thonwirak N; Soonklang K; Sornsamdang G; Auewarakul C; Mahanonda N
    Hum Vaccin Immunother; 2022 Nov; 18(5):2052525. PubMed ID: 35323079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 'Mix and Match' vaccination: Is dengue next?
    Odio CD; Katzelnick LC
    Vaccine; 2022 Oct; 40(45):6455-6462. PubMed ID: 36195473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants.
    Groß R; Zanoni M; Seidel A; Conzelmann C; Gilg A; Krnavek D; Erdemci-Evin S; Mayer B; Hoffmann M; Pöhlmann S; Liu W; Hahn BH; Beil A; Kroschel J; Jahrsdörfer B; Schrezenmeier H; Kirchhoff F; Münch J; Müller JA
    EBioMedicine; 2022 Jan; 75():103761. PubMed ID: 34929493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
    Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ;
    Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data.
    Shaw RH; Stuart A; Greenland M; Liu X; Nguyen Van-Tam JS; Snape MD;
    Lancet; 2021 May; 397(10289):2043-2046. PubMed ID: 33991480
    [No Abstract]   [Full Text] [Related]  

  • 10. Heterologous prime-boost vaccination with adenoviral vector and protein nanoparticles induces both Th1 and Th2 responses against Middle East respiratory syndrome coronavirus.
    Jung SY; Kang KW; Lee EY; Seo DW; Kim HL; Kim H; Kwon T; Park HL; Kim H; Lee SM; Nam JH
    Vaccine; 2018 Jun; 36(24):3468-3476. PubMed ID: 29739720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination.
    Normark J; Vikström L; Gwon YD; Persson IL; Edin A; Björsell T; Dernstedt A; Christ W; Tevell S; Evander M; Klingström J; Ahlm C; Forsell M
    N Engl J Med; 2021 Sep; 385(11):1049-1051. PubMed ID: 34260850
    [No Abstract]   [Full Text] [Related]  

  • 12. Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination.
    Barros-Martins J; Hammerschmidt SI; Cossmann A; Odak I; Stankov MV; Morillas Ramos G; Dopfer-Jablonka A; Heidemann A; Ritter C; Friedrichsen M; Schultze-Florey C; Ravens I; Willenzon S; Bubke A; Ristenpart J; Janssen A; Ssebyatika G; Bernhardt G; Münch J; Hoffmann M; Pöhlmann S; Krey T; Bošnjak B; Förster R; Behrens GMN
    Nat Med; 2021 Sep; 27(9):1525-1529. PubMed ID: 34262158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine.
    Zhang J; He Q; An C; Mao Q; Gao F; Bian L; Wu X; Wang Q; Liu P; Song L; Huo Y; Liu S; Yan X; Yang J; Cui B; Li C; Wang J; Liang Z; Xu M
    Emerg Microbes Infect; 2021 Dec; 10(1):1598-1608. PubMed ID: 34278956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia.
    Logunov DY; Dolzhikova IV; Shcheblyakov DV; Tukhvatulin AI; Zubkova OV; Dzharullaeva AS; Kovyrshina AV; Lubenets NL; Grousova DM; Erokhova AS; Botikov AG; Izhaeva FM; Popova O; Ozharovskaya TA; Esmagambetov IB; Favorskaya IA; Zrelkin DI; Voronina DV; Shcherbinin DN; Semikhin AS; Simakova YV; Tokarskaya EA; Egorova DA; Shmarov MM; Nikitenko NA; Gushchin VA; Smolyarchuk EA; Zyryanov SK; Borisevich SV; Naroditsky BS; Gintsburg AL;
    Lancet; 2021 Feb; 397(10275):671-681. PubMed ID: 33545094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune responses against different variants of SARS-CoV-2 including Omicron following 6 months of administration of heterologous prime-boost COVID-19 vaccine.
    Sapkal G; Kant R; Dwivedi G; Sahay RR; Yadav PD; Deshpande GR; Singh R; Nyayanit DA; Patil DY; Shete-Aich AM; Zaman K; Chaudhari AK; Gupta N; Panda S; Abraham P; Bhargava B
    J Travel Med; 2022 May; 29(3):. PubMed ID: 35244698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Bacterial Mucosal Immunotherapy MV130 Protects Against SARS-CoV-2 Infection and Improves COVID-19 Vaccines Immunogenicity.
    Del Fresno C; García-Arriaza J; Martínez-Cano S; Heras-Murillo I; Jarit-Cabanillas A; Amores-Iniesta J; Brandi P; Dunphy G; Suay-Corredera C; Pricolo MR; Vicente N; López-Perrote A; Cabezudo S; González-Corpas A; Llorca O; Alegre-Cebollada J; Garaigorta U; Gastaminza P; Esteban M; Sancho D
    Front Immunol; 2021; 12():748103. PubMed ID: 34867974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prime-boost vaccination regimens with INO-4800 and INO-4802 augment and broaden immune responses against SARS-CoV-2 in nonhuman primates.
    Walters JN; Schouest B; Patel A; Reuschel EL; Schultheis K; Parzych E; Maricic I; Gary EN; Purwar M; Andrade VM; Doan A; Elwood D; Eblimit Z; Nguyen B; Frase D; Zaidi FI; Kulkarni A; Generotti A; Joseph Kim J; Humeau LM; Ramos SJ; Smith TRF; Weiner DB; Broderick KE
    Vaccine; 2022 May; 40(21):2960-2969. PubMed ID: 35428500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current perspectives for SARS-CoV-2 vaccination efficacy improvement in patients with active treatment against cancer.
    Barrière J; Re D; Peyrade F; Carles M
    Eur J Cancer; 2021 Sep; 154():66-72. PubMed ID: 34243079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of COVID-19 vaccination in patients with non-alcoholic fatty liver disease (CHESS2101): A multicenter study.
    Wang J; Hou Z; Liu J; Gu Y; Wu Y; Chen Z; Ji J; Diao S; Qiu Y; Zou S; Zhang A; Zhang N; Wang F; Li X; Wang Y; Liu X; Lv C; Chen S; Liu D; Ji X; Liu C; Ren T; Sun J; Zhao Z; Wu F; Li F; Wang R; Yan Y; Zhang S; Ge G; Shao J; Yang S; Liu C; Huang Y; Xu D; Li X; Ai J; He Q; Zheng MH; Zhang L; Xie Q; Rockey DC; Fallowfield JA; Zhang W; Qi X
    J Hepatol; 2021 Aug; 75(2):439-441. PubMed ID: 33905793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adopting an heterologous prime-boost strategy in COVID-19 vaccination: the need for locally generated evidence in Africa.
    Oboh MA; Omoleke S; Salami K
    Pan Afr Med J; 2022; 41():148. PubMed ID: 35519174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.